Lv41
768 积分 2022-07-21 加入
Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report
51分钟前
已完结
Landmark ctDNA Molecular Response Represents an Early Predictor of Immunotherapy Outcomes in Lung Cancer: A Clinical Validity Study
52分钟前
已关闭
Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial
1小时前
已关闭
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation
1小时前
已完结
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
1小时前
已完结
Subcutaneous delivery of monoclonal antibodies: How do we get there?
19天前
已完结
Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors
20天前
已完结
Leveraging advanced preparation of oncology medications: Decreasing turnaround-times in an outpatient infusion center
20天前
已完结
Five historical innovations that have shaped modern cardiothoracic surgery
29天前
已关闭
Co-medications and gut microbiome in NSCLC immunotherapy
1个月前
已关闭
皖公网安备34019202002308
